JP Morgan Chase
PACB icon

JP Morgan Chase’s Pacific Biosciences PACB Stock Holding History

JP Morgan Chase’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,200
Closed -$56K – 6875
2021
Q3 		$56K Buy
+2,200
New +$65.2K ﹤0.01% 5802

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase's PACB Position: Q1 2026 in Review

JP Morgan Chase reduced its Pacific Biosciences (PACB) stake by 70% in Q1 2026, selling an estimated $570K and leaving 138,504 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

JP Morgan Chase first reported a position in PACB in Q2 2013 and has held it in 47 quarters since. The position peaked at $19.6M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • JP Morgan Chase held 138,504 shares of Pacific Biosciences worth $175K as of Q1 2026.
  • JP Morgan Chase sold 318,404 Pacific Biosciences shares in Q1 2026, an estimated $570K.
  • Pacific Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5541 holding.
  • JP Morgan Chase first reported a position in Pacific Biosciences in Q2 2013 and has held it in 47 quarters since.
  • JP Morgan Chase's Pacific Biosciences position peaked at $19.6M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.